Drug Trial Radar · NCT02671175
Post-discharge Malaria Chemoprevention(PMC) Study
Last checked: Nov 20, 2026Latest source record: Jun 4, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,049
Actual
Start
May 20, 2016
Primary completion
Oct 24, 2018
Study completion Dec 12, 2018
Sponsor
- Lead sponsor
- Liverpool School of Tropical MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The Research Council of Norway; Kenya Medical Research Institute; Makerere University
- First posted
- Feb 2, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, up to 60 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates the efficacy and safety of 3 months of malaria chemoprevention post-discharge using dihydroartemisinin piperaquine (DHA-P) in children under 5 years of age admitted with severe anemia. One half will receive monthly DHA-P and the other half placebo.
Conditions
- Malaria
- Severe Anemia
Interventions
dihydroartemisinin-piperaquineDrug
Children in both arms will receive standard in-hospital care for severe anaemia (blood transfusion, often combined with quinine or artesunate IV/IM). All children will then receive a 3-day course of AL (whether they initially had malaria or not), which will be started in-hospital as soon as they are able to take oral medication, and will be completed at home after discharge. At 2 weeks after enrolment surviving children will be randomized to receive either a standard 3-day courses of dihydroartemisinin-piperaquine (Eurartesim®, Sigma Tau, Italy) or an identical placebo regimen at 2, 6 and 10 weeks after enrolment.
dihydroartemisinin-piperaquine placeboDrug
Children will receive standard in-hospital care for severe anaemia (blood transfusion, often combined with quinine or artesunate IV/IM). All children will then receive a 3-day course of AL (whether they initially had malaria or not), which will be started in-hospital as soon as they are able to take oral medication, and will be completed at home after discharge. At 2 weeks after enrolment surviving children will be randomized to receive either a standard 3-day courses of dihydroartemisinin-piperaquine (Eurartesim®, Sigma Tau, Italy) or an identical placebo regimen at 2, 6 and 10 weeks after enrolment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- All-cause deaths or all-cause re-admissions by 26 weeks from randomization (composite primary outcome).Time frame: 6 months
Locations
9 sites in 2 countries. Site status is shown where the registry gives one.
Jaramogi Oginga Odinga Teaching and Referral Hospital
Kisumu, Kenya
Homa Bay County Referral Hospital
Homa Bay, Homa Bay County, Kenya
Migori County Referral Hospital
Migori, Migori County, Kenya
Siaya County Referral Hospital
Siaya, Siaya County, Kenya
Hoima Regional Referral Hospital
Hoima, Uganda
Jinja Regional Referral Hospital
Jinja, Uganda
Kamuli Mission Hospital
Kamuli, Uganda
Masaka Regional Referral Hospital
Masaka, Uganda
Mubende Regional Referral Hospital:
Mubende, Uganda
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.